Xiaocui Huang

Xiaocui Huang

Auto-generated profile, based on publicly available information

Xiaocui Huang

Chengdu Jinjiang District Maternal and Child Healthcare Hospital, Chengdu, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
YZYiduo Zhang
Yiduo Zhang
XHXiaocui Huang
Xiaocui Huang
CLChao Li
Chao Li
JZJing Zhang
Jing Zhang
XYXingnan Yu
Xingnan Yu
FYFan Yu
Fan Yu
Background: Bone turnover markers (BTMs) have been studied for application in clinical medicine. However, BTMs in children are challenging, and few studies explore these BTMs in children. The application of BTMs is complicated mainly due to pre‐analytical factors, variable reference intervals of age‐ and sex‐related BTMs for adolescents and children in different regions and laboratories. Therefore, laboratory testing of BTMs is critical for understanding pediatric bone development and metabolism, which provides additional information about bone development and diseases.Methods: Literature search was conducted using the MeSH term “child” combined with the terms that bone turnover markers such as “osteocalcin,” “Procollagen type I N‐terminal propeptide,” “procollagen type I C‐terminal propeptide,” “osteocalcin,” “N‐terminal cross‐linked telopeptide,” and “C‐terminal cross‐linked telopeptide,” Several databases including Web of Science, Google Scholar, and PubMed were searched to obtain the relevant studies.Results: BTMs represent the combined effects of skeletal development, growth, and remodeling in children, which can be used in clinical pediatrics to assist in the diagnosis and prognosis of bone metabolic disorders.Conclusion: BTMs are clearly helpful for diagnosis and monitoring of bone growth and development as well as bone metabolic disorders.

28 July 2023 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
YZYiduo Zhang
Yiduo Zhang
JZJing Zhang
Jing Zhang
XHXiaocui Huang
Xiaocui Huang
XYXingnan Yu
Xingnan Yu
YLYe Li
Ye Li
WZWenjie Zhou
Wenjie Zhou
Objectives. To determine the bone metabolic marker changes from childhood to adolescence and to provide reference values for monitoring bone development in children in Southwest China. Methods. We surveyed 703 participants attending physical examinations from April 2019 and August 2021. Twenty-eight participants were excluded for lack of laboratory tests, and 14 people were excluded for diseases that might affect bone metabolism. A total of 661 children were selected for the study. According to the main developmental periods, the children were divided into preschool, preadolescence, and adolescence groups. Serum bone turnover markers including β-isomerized C-terminal telopeptide of type I collagen (β-CTx), N-terminal midfragment of osteocalcin (N-MID), and procollagen type 1 N-propeptide (P1NP) as well as growth and development indices such as serum calcium (Ca), phosphorus (Pi), alkaline phosphatase (ALP), and vitamin D were measured. The changes in bone metabolism-related markers and the correlations between the indices were analyzed. Results. During the development in boys, the levels of β-CTx and N-MID increased with age from preschool to adolescence, while the levels of P1NP decreased and then increased. In girls, the levels of β-CTx and N-MID plateaued in early adolescence and showed little change in subsequent adolescence, while the levels of P1NP exhibited a downward trend. The correlations between bone metabolism markers and vitamin D were not significant. Conclusions. The levels of bone metabolism markers differed between boys and girls. Reference intervals can be used as essential tools to examine the levels of bone metabolism markers reasonably.

19 July 2023 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
CLChao Li
Chao Li
YCYali Cui
Yali Cui
WZWenjie Zhou
Wenjie Zhou
YZYiduo Zhang
Yiduo Zhang
XHXiaocui Huang
Xiaocui Huang
FYFan Yu
Fan Yu
Objective. Previous studies suggested that the level of bone turnover markers (BTMs) could be altered in patients with nonalcoholic fatty liver disease (NAFLD). We aim to provide a comprehensive understanding on the associations between BTMs and NAFLD in adults with a meta-analysis. Methods. Articles published up to January 31, 2023, were systematically searched in PubMed, Web of Science, Cochrane database, Embase, and CNKI. The search formula is as follows: “nonalcoholic fatty liver disease” combined with the terms that bone turnover markers such as “osteocalcin,” “collagen type I trimeric cross-linked peptide,” and “procollagen type I N-terminal peptide.” Stata 15.0 software was used to calculate the pooled OR (95% CI) and perform the heterogeneity test, sensitivity analysis, and publication bias. Results. We identified 18 studies with a total of 12,310 participants. Statistical differences were found between patients with NAFLD compared to the control group for osteocalcin (n = 15 studies; SMD: −0.69; 95% CI: −0.73–−0.64; ), procollagen type I N-terminal propeptide (n = 5 studies; SMD: −0.40; 95% CI: −0.80−−0.00; ), and collagen type I cross-linked C-telopeptide (n = 7 studies; SMD: −0.16; 95% CI: −0.23−−0.09); ). Conclusion. Bone turnover markers were lower in patients with NAFLD compared to the control group.

1 January 2024 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
FYFan Yu
Fan Yu
XHXiaocui Huang
Xiaocui Huang
YTYuanting Tang
Yuanting Tang
YZYiduo Zhang
Yiduo Zhang
QLQing Li
Qing Li
YJYongmei Jiang
Yongmei Jiang
Background: Pre‐eclampsia is a severe pregnancy complication affecting about 4%–5% of pregnancies, but the causes and clinical management were full of controversial. Bone turnover markers (BTMs) were sensitive indicators for estimating bone metabolism and were found to be changed in many pregnancy‐related diseases. However, the characteristic and prognostic value of serum BTMs with pre‐eclampsia was uncovered.Methods: A multicenter prospective cohort study was performed in three different hospitals in West China. Pre‐eclampsia patients and healthy pregnant women were recruited from January 2023 to January 2024. Clinical information of included participants was collected, and serum BTM levels were detected by electrochemiluminescence immunoassay. Clinical outcomes including disease aggravation (severe pre‐eclampsia, eclampsia, and HELLP syndrome), low live birth weight (LBW), and premature delivery were followed up.Results: A total of 69 pre‐eclampsia patients and 75 healthy pregnant women were recruited finally, and 48 pre‐eclampsia patients and 48 healthy controls who matched for age and gestational weeks were selected among them. The pre‐eclampsia patients had elevated BTM levels compared with healthy controls. ß‐CTX was an independent risk factor for disease aggravation, LBW, and premature delivery among pre‐eclampsia patients. ß‐CTX was a valuable predictive factor for disease aggravation, LBW, and premature delivery among pre‐eclampsia patients (AUC were 0.772, 0.768, and 0.930, respectively, and p values were 0.001, 0.002, and < 0.001, respectively).Conclusion: Pre‐eclampsia patients may have an activated bone metabolism status compared with healthy controls. Pre‐eclampsia patients with elevated bone resorptive marker ß‐CTX should pay more attention to the risk of disease aggravation and adverse pregnancy outcomes.